...Jason, good to see you. Great to be here again this year and great to see everyone in the audience here, and have a chance to talk through our program. So, yes, Rocket Pharma, we're a gene therapy company. Before Rocket, I was actually at Novartis working on CAR-T, working on Kymriah and learned a lot about the industry, especially with regard to CMC and clinical trial requirements for an industry-grade trial converting early cell and gene therapy data into something that is going to treat thousands of patients. Learned a lot, applied it to Rocket in the early days and the premise of starting Rocket was instead of thinking of a platform, a science platform, which is how a lot of gene and cell therapy company start. We were started by a group of health care providers and physicians who thought about disease states, where the high unmet need is, where we can attack a protein in a cell that leads to direct clinical benefit and where we could try to address the most number of patients possible....
